ProfoundBio Overview
- Year Founded
-
2018
- Status
-
Acquired/Merged
- Employees
-
110
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.91B
ProfoundBio General Information
Description
Developer of novel targeted therapeutics intended to treat patients with cancer. The company develops advancing novel classes of therapeutics that are designed to leverage the immune system to eradicate cancer, enabling patients to get better treatment with curative potential.
Contact Information
Website
www.profoundbio.comCorporate Office
- 401 Terry Avenue North
- Seattle, WA 98109
- United States
Corporate Office
- 401 Terry Avenue North
- Seattle, WA 98109
- United States
ProfoundBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 21-May-2024 | $1.91B | Completed | Clinical Trials - Phase 2 | ||
| 4. Later Stage VC (Series B) | 09-Feb-2024 | Completed | Clinical Trials - Phase 2 | |||
| 3. Early Stage VC (Series A1) | 14-Apr-2022 | Completed | Product Development | |||
| 2. Early Stage VC (Series A) | 16-Jun-2021 | $55.5M | $68M | Completed | Product Development | |
| 1. Early Stage VC | 20-Aug-2020 | $12.5M | $12.5M | Completed | Startup |
ProfoundBio Patents
ProfoundBio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025117639-A1 | Antibodies and methods for ptk7 detection | Inactive | 27-Nov-2023 | ||
| WO-2025072486-A1 | Dosage of antibody drug conjugate rinatabart sesutecan | Inactive | 26-Sep-2023 | ||
| WO-2025072406-A1 | Ptk7 binding agents, conjugates thereof and methods of using the same | Inactive | 26-Sep-2023 | ||
| WO-2025064521-A1 | Ultrafiltration / diafiltration purification methods | Inactive | 18-Sep-2023 | ||
| WO-2024149345-A1 | Linkers, drug linkers and conjugates thereof and methods of using the same | Inactive | 11-Jan-2023 | A61K47/68031 |
ProfoundBio Signals
ProfoundBio Former Investors (22)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Ally Bridge Group | Growth/Expansion | Minority | ||
| B Capital China | Venture Capital | Minority | ||
| Chang'an Fund Management | Venture Capital | Minority | ||
| Dragonball Capital | Corporate Venture Capital | Minority | ||
| Gaorong Ventures | Venture Capital | Minority |
ProfoundBio FAQs
-
When was ProfoundBio founded?
ProfoundBio was founded in 2018.
-
Where is ProfoundBio headquartered?
ProfoundBio is headquartered in Seattle, WA.
-
What is the size of ProfoundBio?
ProfoundBio has 110 total employees.
-
What industry is ProfoundBio in?
ProfoundBio’s primary industry is Drug Discovery.
-
Is ProfoundBio a private or public company?
ProfoundBio is a Private company.
-
What is the current valuation of ProfoundBio?
The current valuation of ProfoundBio is .
-
What is ProfoundBio’s current revenue?
The current revenue for ProfoundBio is .
-
How much funding has ProfoundBio raised over time?
ProfoundBio has raised $250M.
-
Who are ProfoundBio’s investors?
Ally Bridge Group, B Capital China, Chang'an Fund Management, Dragonball Capital, and Gaorong Ventures are 5 of 22 investors who have invested in ProfoundBio.
-
When was ProfoundBio acquired?
ProfoundBio was acquired on 21-May-2024.
-
Who acquired ProfoundBio?
ProfoundBio was acquired by Genmab.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process